Caribou Biosciences, Inc.

NASDAQ:CRBU

1.72 (USD) • At close September 6, 2024
Bedrijfsnaam Caribou Biosciences, Inc.
Symbool CRBU
Munteenheid USD
Prijs 1.72
Beurswaarde 155,424,016
Dividendpercentage 0%
52-weken bereik 1.5 - 8.33
Industrie Biotechnology
Sector Healthcare
CEO Dr. Rachel E. Haurwitz Ph.D.
Website https://cariboubio.com

An error occurred while fetching data.

Over Caribou Biosciences, Inc.

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial

Vergelijkbare Aandelen

ANI Pharmaceuticals, Inc. logo

ANI Pharmaceuticals, Inc.

ANIP

60.51 USD

Century Therapeutics, Inc. logo

Century Therapeutics, Inc.

IPSC

1.46 USD

Inhibrx, Inc. logo

Inhibrx, Inc.

INBX

15.06 USD

Cullinan Oncology, Inc. logo

Cullinan Oncology, Inc.

CGEM

17.98 USD

Aura Biosciences, Inc. logo

Aura Biosciences, Inc.

AURA

7.78 USD

Intercept Pharmaceuticals, Inc. logo

Intercept Pharmaceuticals, Inc.

ICPT

19 USD

Nano-X Imaging Ltd. logo

Nano-X Imaging Ltd.

NNOX

5.9 USD

Tango Therapeutics, Inc. logo

Tango Therapeutics, Inc.

TNGX

10.89 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)